Publications by authors named "Javier Bachiller-Corral"
Characterization of flare-ups and impact of garetosmab in adults with fibrodysplasia ossificans progressiva: a post hoc analysis of the randomized, double-blind, placebo-controlled LUMINA-1 trial.
J Bone Miner Res
September 2024
Article Synopsis
- Fibrodysplasia ossificans progressiva (FOP) is a rare disorder causing painful flare-ups and abnormal bone growth, known as heterotopic ossification (HO).
- In a clinical trial, patients receiving the anti-activin A antibody garetosmab experienced fewer severe and lengthy flare-ups compared to those given a placebo, leading to a notable difference in quality of life.
- The study found that 71% of placebo patients had flare-ups linked to new HO lesions, while garetosmab reduced the severity, duration, and frequency of these flare-ups throughout the trial.
Background: Rheumatic and musculoskeletal diseases (RMDs) are chronic diseases that may alternate between asymptomatic periods and flares. These conditions require complex treatments and close monitoring by rheumatologists to mitigate their effects and improve the patient's quality of life. Often, delays in outpatient consultations or the patient's difficulties in keeping appointments make such close follow-up challenging.
View Article and Find Full Text PDFAgreement between local and central anti-synthetase antibodies detection: results from the Classification Criteria of Anti-Synthetase Syndrome project biobank.
Clin Exp Rheumatol
February 2024
Article Synopsis
- - The CLASS project aims to develop data-driven classification criteria for anti-synthetase syndrome (ASSD) by assessing the effectiveness of local immunoassays for detecting anti-aminoacyl tRNA synthetase antibodies (anti-ARS) in real-world settings.
- - Researchers collected 787 serum samples from various centers and compared local testing results with a central standard using immunoprecipitation and other methods to evaluate tests' sensitivity, specificity, and predictive values.
- - While local detection of anti-Jo1 antibodies showed high reliability, the agreement for anti-non-Jo1 antibodies varied, indicating some local tests may not align well with central definitions.
Objective: Health-related quality of life (HRQoL) is an important indicator of population health and can measure the impact of medical actions. The main objective of this study was to determine the HRQoL of patients with rheumatic diseases (RD) and compare it with that of the general population.
Methods: Observational, cross-sectional, single-center study, with consecutive inclusion of outpatients over 18 years of age seen at a Rheumatology hospital-based outpatient clinic in Madrid.
Article Synopsis
- - Fibrodysplasia ossificans progressiva (FOP) is a rare condition that causes painful heterotopic ossification in connective tissues, leading to disability.
- - In the LUMINA-1 phase 2 trial, adults with FOP were given either garetosmab (an activin A-blocking antibody) or a placebo over two 28-week periods, focusing on safety and effects on HO lesions.
- - Although the primary efficacy endpoint was not met in the first period, garetosmab significantly reduced the development of new HO lesions in the second period compared to placebo, with ongoing investigations into its effectiveness.
The aim of this study is to assess the relationship between myositis specific (MSA) and myositis associated (MAA) antibodies and diagnosis (including idiopathic inflammatory myopathies [IIM] and other systemic autoimmune diseases [SAID]), and to explore the impact of antibody signal intensity in diagnostic accuracy. We retrospectively reviewed all the serum samples obtained from patients tested for MSA/MAA by line immunoassay (LIA) between 01/01/2018 and 31/12/2020 in Ramón y Cajal University Hospital (Spain). Clinical true positive (CTP) MSAs and MAAs were defined as those patients with IIM or SAID with phenotypes expected of that MSA/MAA.
View Article and Find Full Text PDFArticle Synopsis
- This study investigates the risk factors for severe COVID-19 in patients with immune-mediated rheumatic diseases, focusing on different types of autoimmune conditions and chronic arthritis.
- Conducted as a multicenter observational study in Madrid, it involved 523 patients diagnosed with severe COVID-19, analyzing their outcomes based on various demographic and clinical factors.
- Key findings revealed that male gender, older age, and certain comorbidities, along with specific medications like corticosteroids and rituximab, were linked to worse COVID-19 outcomes, while treatments like methotrexate showed no negative impact.
Secukinumab is a novel anti-IL17 biologic treatment approved for the treatment of psoriatic arthritis (PsA). The purpose of the present study is to identify factors that can condition the retention rate of this drug in a real-world scenario. Methods: A multicentric retrospective study was conducted based on the registries of consecutive patients diagnosed with PsA who started secukinumab from January 2016 to December 2018.
View Article and Find Full Text PDFObjectives: To define the clinical spectrum time-course and prognosis of non-Asian patients positive for anti-MDA5 antibodies.
Methods: We conducted a multicentre, international, retrospective cohort study.
Results: 149 anti-MDA5 positive patients (median onset age 53 years, median disease duration 18 months), mainly females (100, 67%), were included.
Background: This study aimed to assess the baseline characteristics and clinical outcomes of coronavirus disease 2019 (COVID-19) in pediatric patients with rheumatic and musculoskeletal diseases (RMD) and identify the risk factors associated with symptomatic or severe disease defined as hospital admission, intensive care admission or death.
Methods: An observational longitudinal study was conducted during the first year of the SARS-CoV-2 pandemic (March 2020-March 2021). All pediatric patients attended at the rheumatology outpatient clinics of six tertiary referral hospitals in Madrid, Spain, with a diagnosis of RMD and COVID-19 were included.
Remission Induced by TNF Inhibitors Plus Methotrexate is Associated With Changes in Peripheral Naïve B Cells in Patients With Rheumatoid Arthritis.
Front Med (Lausanne)
June 2021
Biological therapies, such as TNF inhibitors (TNFi), are increasing remission (REM) rates in rheumatoid arthritis (RA) patients, although these are still limited. The aim of our study was to analyze changes in the profile of peripheral blood mononuclear cells (PBMC) in patients with RA treated with TNFi in relation to the clinical response. This is a prospective and observational study including 78 RA patients starting the first TNFi.
View Article and Find Full Text PDFObjective: To describe the cohort of patients with inflammatory rheumatic diseases (IRD) hospitalized due to SARS-CoV-2 infection in the Ramón y Cajal Hospital, and to determine the increased risk of severe coronavirus disease 2019 (COVID-19) in patients with no IRD.
Methods: This is a retrospective single-center observational study of patients with IRD actively monitored in the Department of Rheumatology who were hospitalized due to COVID-19.
Results: Forty-one (1.
Article Synopsis
- The study aimed to identify factors linked to COVID-19 deaths in individuals with rheumatic diseases by analyzing data from a physician-reported registry between March and July 2020.
- Among 3729 patients, 10.5% died from COVID-19, with key factors for increased mortality including older age, male sex, certain comorbid conditions, and specific disease activity levels.
- Medications played a critical role, with higher death odds associated with certain treatments (like rituximab) and higher disease activity, emphasizing the need for effective disease management for this population.
Cardiovascular mortality and cardiovascular event rates in patients with inflammatory rheumatic diseases in the CARdiovascular in rheuMAtology (CARMA) prospective study-results at 5 years of follow-up.
Rheumatology (Oxford)
June 2021
Objectives: To determine cardiovascular (CV) mortality and incidence of the first CV event (CVE) in patients with chronic inflammatory rheumatic diseases (CIRD) after 5 years of follow-up.
Methods: This is an analysis of the CARdiovascular in rheMAatology (CARMA) study after 5 years of follow-up. It includes patients with RA (n = 775), AS (n = 738) and PsA (n = 721), and individuals without CIRD (n = 677) attending outpatient rheumatology clinics from 67 public hospitals in Spain.
High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study.
Rheumatol Int
December 2020
Article Synopsis
- * Out of 76 patients screened, 13 (17.1%) had suspected or confirmed COVID-19, with a median age of 68 years, and many suffered from other serious health issues like pulmonary involvement.
- * The findings revealed a high hospitalization rate (61.5%) among those infected, with severe conditions leading to critical illness and a mortality rate of 23.1%, suggesting that rituximab treatment could be a risk factor for worse outcomes in these patients.
Fibrodysplasia ossificans progressiva (FOP) is an extremely rare congenital form of heterotopic ossification (HO), caused by heterozygous mutations in the activin A type I receptor (ACVR1), that encodes the bone morphogenetic protein (BMP) type I receptor ALK2. These mutations enable ALK2 to induce downstream signaling in response to activins, thereby turning them into bone-inducing agents. To date, there is no cure for FOP.
View Article and Find Full Text PDFAntisynthetase syndrome (ASSD) is a rare clinical condition that is characterized by the occurrence of a classic clinical triad, encompassing myositis, arthritis, and interstitial lung disease (ILD), along with specific autoantibodies that are addressed to different aminoacyl tRNA synthetases (ARS). Until now, it has been unknown whether the presence of a different ARS might affect the clinical presentation, evolution, and outcome of ASSD. In this study, we retrospectively recorded the time of onset, characteristics, clustering of triad findings, and survival of 828 ASSD patients (593 anti-Jo1, 95 anti-PL7, 84 anti-PL12, 38 anti-EJ, and 18 anti-OJ), referring to AENEAS (American and European NEtwork of Antisynthetase Syndrome) collaborative group's cohort.
View Article and Find Full Text PDFObjectives: To assess the plasma apolipoprotein B/apolipoprotein A1 ratio and its potential association with cardiovascular events (CVE) in patients with rheumatoid arthritis (RA).
Methods: A baseline analysis was made of the CARdiovascular in rheuMAtology Project (CARMA), a 10-year prospective study evaluating the presence of at least one CVE in 775 Spanish patients with RA. Of them, 29 had already experienced CVE prior to the inclusion in the study.
Impact of Comorbidity on Physical Function in Patients With Ankylosing Spondylitis and Psoriatic Arthritis Attending Rheumatology Clinics: Results From a Cross-Sectional Study.
Arthritis Care Res (Hoboken)
June 2020
Objective: To evaluate the impact of comorbidities on physical function in patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA).
Methods: This was a cross-sectional analysis of the baseline visit from the Cardiovascular in Rheumatology study. Multivariate models with physical function as the dependent variable (Bath Ankylosing Spondylitis Functional Index and Health Assessment Questionnaire for AS and PsA, respectively) were performed.